Patents by Inventor Jeremy D. Heidel

Jeremy D. Heidel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and use of EPAS1 inhibitors
    Patent number: 8114983
    Abstract: The present invention relates to inhibitors of endothelial PAS domain protein 1 (EPAS1), and methods and compositions related to the EPAS1 inhibitors. In certain embodiments, the EPAS1 inhibitors include nucleic acids, such as for example siRNAs.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: February 14, 2012
    Assignee: Calando Pharmaceuticals, Inc.
    Inventors: Mark E. Davis, Jeremy D. Heidel, Joanna Yi-Ching Liu
  • Compositions and use of EPAS1 inhibitors
    Publication number: 20100010071
    Abstract: The present invention relates to inhibitors of endothelial PAS domain protein 1 (EPAS1), and methods and compositions related to the EPAS1 inhibitors. In certain embodiments, the EPAS1 inhibitors include nucleic acids, such as for example siRNAs.
    Type: Application
    Filed: April 3, 2009
    Publication date: January 14, 2010
    Applicant: Calando Pharmaceuticals, Inc.
    Inventors: Mark E. Davis, Jeremy D. Heidel, Joanna Yi-Ching Liu
  • Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
    Publication number: 20090169638
    Abstract: The present application relates to inhibitors of ribonucleotide reductase subunit 2 (R2), and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs.
    Type: Application
    Filed: September 22, 2008
    Publication date: July 2, 2009
    Applicant: Calando Pharmaceuticals, Inc.
    Inventors: Mark E. Davis, Jeremy D. Heidel, John J. Rossi
  • Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
    Patent number: 7427605
    Abstract: The present application relates to inhibitors of ribonucleotide reductase subunit 2 (R2), and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: September 23, 2008
    Assignee: Calando Pharmaceuticals, Inc.
    Inventors: Mark E. Davis, Jeremy D. Heidel, John J. Rossi